Advanced Oncotherapy Management
Management criteria checks 2/4
Advanced Oncotherapy's CEO is Nicolas Serandour, appointed in Oct 2016, has a tenure of 7.08 years. directly owns 0.4% of the company’s shares, worth £38.10K. The average tenure of the management team and the board of directors is 8.3 years and 8.6 years respectively.
Key information
Nicolas Serandour
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.1yrs |
| CEO ownership | 0.4% |
| Management average tenure | 8.3yrs |
| Board average tenure | 8.6yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | -UK£33m |
| Mar 31 2022 | n/a | n/a | -UK£31m |
| Dec 31 2021 | UK£503k | UK£300k | -UK£29m |
| Sep 30 2021 | n/a | n/a | -UK£28m |
| Jun 30 2021 | n/a | n/a | -UK£26m |
| Mar 31 2021 | n/a | n/a | -UK£26m |
| Dec 31 2020 | UK£336k | UK£300k | -UK£25m |
| Sep 30 2020 | n/a | n/a | -UK£24m |
| Jun 30 2020 | n/a | n/a | -UK£22m |
| Mar 31 2020 | n/a | n/a | -UK£21m |
| Dec 31 2019 | UK£401k | UK£247k | -UK£21m |
| Sep 30 2019 | n/a | n/a | -UK£21m |
| Jun 30 2019 | n/a | n/a | -UK£21m |
| Mar 31 2019 | n/a | n/a | -UK£21m |
| Dec 31 2018 | UK£1m | UK£233k | -UK£21m |
| Jun 30 2018 | n/a | n/a | -UK£18m |
| Mar 31 2018 | n/a | n/a | -UK£16m |
| Dec 31 2017 | UK£239k | UK£215k | -UK£14m |
| Jun 30 2017 | n/a | n/a | -UK£12m |
| Mar 31 2017 | n/a | n/a | -UK£11m |
| Dec 31 2016 | UK£208k | UK£180k | -UK£10m |
Compensation vs Market: Insufficient data to establish whether Nicolas's total compensation is reasonable compared to companies of similar size in the UK market.
Compensation vs Earnings: Nicolas's compensation has increased whilst the company is unprofitable.
CEO
Nicolas Serandour (48 yo)
7.1yrs
Tenure
UK£502,965
Compensation
Mr. Nicolas Serandour has been the Chief Executive Officer of Advanced Oncotherapy Plc since October 27, 2016. Mr. Serandour served as the Chief Financial Officer and Chief Operating Officer at Advanced On...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 17.4yrs | UK£434.42k | 1.74% £ 165.2k | |
| CEO & Executive Director | 7.1yrs | UK£502.97k | 0.40% £ 38.1k | |
| Executive Director | no data | UK£397.72k | 0.28% £ 27.0k | |
| COO & President of Europe | 6.4yrs | no data | no data | |
| Senior Vice-President of Accounting | 10.9yrs | no data | no data | |
| Senior Vice-President of Corporate Finance | no data | no data | no data | |
| Director of Technical & Engineering | no data | no data | no data | |
| Vice President of Investor and Public Relations | 6.9yrs | no data | no data | |
| Director of Human Resources | 7yrs | no data | no data | |
| Managing Director of ADAM | 15.4yrs | no data | no data | |
| Head of Physics Group | 10.2yrs | no data | no data | |
| Head of Radiofrequency Group | 9.6yrs | no data | no data |
8.3yrs
Average Tenure
76yo
Average Age
Experienced Management: AVO's management team is seasoned and experienced (8.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 17.4yrs | UK£434.42k | 1.74% £ 165.2k | |
| CEO & Executive Director | 9.3yrs | UK£502.97k | 0.40% £ 38.1k | |
| Executive Director | 8yrs | UK£397.72k | 0.28% £ 27.0k | |
| Member of Medical Advisory Board | 5.8yrs | UK£15.00k | no data | |
| Senior Independent Director | 6.8yrs | UK£67.50k | 0.18% £ 17.2k | |
| Member of Medical Advisory Board | 10.1yrs | no data | no data | |
| Independent Non-Executive Director | 10.1yrs | UK£62.50k | 0.75% £ 71.3k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 10.6yrs | UK£50.00k | 1.54% £ 146.2k | |
| Independent Chairman of Medical Advisory Board & Non-Executive Director | 6.8yrs | UK£40.00k | 0.86% £ 81.8k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 5.3yrs | UK£30.00k | no data |
8.6yrs
Average Tenure
73yo
Average Age
Experienced Board: AVO's board of directors are considered experienced (8.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/26 19:36 |
| End of Day Share Price | 2023/08/30 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Advanced Oncotherapy plc is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Redhead | goetzpartners securities Limited |
| Jon Levinson | Growth Equities & Company Research |
| Yingheng Chen | Hardman & Co. |